On World Health Day,a 31 country Ipsos Health Service Report 2024 showsthe health concernsbothering Indians most were ...

近年来，以司美格鲁肽、替尔泊肽为代表的GLP-1受体激动剂在减重治疗领域取得突破性进展，成功撬动全球千亿美元市场规模。然而，这类药物伴随的肌肉流失等不良反应，成为临床应用中需要重视的问题，也推动着减重治疗向更优化的方向发展。为应对这一挑战，全球药企正 ...

Considering the current chart structure, weak momentum, and cautious global sentiment, it seems the bears are likely to ...

Sensex, Nifty extended decline in Friday's trade amid global trade war fears, eroding investor wealth by over Rs 9 lakh crore ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Investing.com -- Shares of Zealand Pharma (CSE: ZELA) fell on Tuesday following the release of interim topline results from Gubra’s (CSE: GUBRA) multiple ascending dose (MAD) study of its ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...

Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...

Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of ...

Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show ... Investors and patients will have to wait sometime for such products to ...

Investing.com -- Morgan Stanley (NYSE:MS) upgraded its rating on Zealand Pharma (NASDAQ:ZEAL) shares to Overweight from Equal Weight, highlighting a “long-term obesity potential” unlocked by the ...